The excruciating joint pain that can result from infection with the recently discovered Chikungunya virus can last for months or even years. Researchers from Oregon Health & Science University and…
Latest News
-
-
Patients receiving efgartigimod, a drug being studied for the treatment of chronic primary immune thrombocytopenia (ITP), had a much greater increase in platelet counts, which are essential for clotting and…
-
A recent research found that the novel medication modakafusp alf offers early promise in treating the bone marrow malignancy multiple myeloma. At the 2022 American Society of Hematology (ASH) Annual…
-
Uncategorized
Patients with high-risk CLL, benefit from receiving three-drug combination treatment: Study
A three-drug regimen that produced remarkable remissions in chronic lymphocytic leukaemia (CLL) patients in a clinical research is extremely helpful in patients with high-risk variations of the illness, according to…
-
Modakafusp alfa, a novel medicine, has shown early promise in treating multiple myeloma, a kind of bone marrow cancer, according to findings presented at the 2022 American Society of Hematology…
-
In two clinical investigations, researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai discovered that a new therapy that triggers the immune system to…